Literature DB >> 7573260

Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study.

D H Wide-Swensson1, I Ingemarsson, N O Lunell, A Forman, K Skajaa, B Lindberg, S Lindeberg, K Marsàl, K E Andersson.   

Abstract

OBJECTIVE: Our purpose was to study the effects of isradipine, a dihydropyridine calcium channel blocker, on mother and fetus in the treatment of hypertensive disorders of pregnancy. STUDY
DESIGN: The investigation was performed as a two-group, parallel, double-blind multicenter study of isradipine versus placebo. Fifty-four women were randomized to treatment with isradipine slow-release capsules given orally 5 mg twice a day and 57 to a placebo group.
RESULTS: Isradipine lowered the maternal mean arterial blood pressure effectively in women with nonproteinuric hypertension but did not do so in women with proteinuria at recruitment or appearing during treatment. Blood flow in the umbilical artery and maternal renal and liver function were not influenced by treatment. Isradipine had few side effects and was well tolerated.
CONCLUSION: Calcium channel blockade with isradipine is effective for treatment of nonproteinuric hypertension but not in preeclampsia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573260     DOI: 10.1016/0002-9378(95)90357-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

Review 1.  Fortnightly review: management of hypertension in pregnancy.

Authors:  L A Magee; M P Ornstein; P von Dadelszen
Journal:  BMJ       Date:  1999-05-15

Review 2.  Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy.

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  World J Nephrol       Date:  2014-11-06

Review 3.  Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?

Authors:  S M Khedun; B Maharaj; J Moodley
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

4.  Optimal blood pressure target to prevent severe hypertension in pregnancy: A systematic review and meta-analysis.

Authors:  Makiko Abe; Hisatomi Arima; Yuichi Yoshida; Ako Fukami; Atsushi Sakima; Hirohito Metoki; Kazuhiro Tada; Asako Mito; Satoshi Morimoto; Hirotaka Shibata; Masashi Mukoyama
Journal:  Hypertens Res       Date:  2022-02-08       Impact factor: 3.872

Review 5.  Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

Review 6.  Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths.

Authors:  Mehnaz Jabeen; Mohammad Yawar Yakoob; Aamer Imdad; Zulfiqar A Bhutta
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

7.  Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses.

Authors:  Jeffrey N Bone; Akshdeep Sandhu; Edgardo D Abalos; Asma Khalil; Joel Singer; Sarina Prasad; Shazmeen Omar; Marianne Vidler; Peter von Dadelszen; Laura A Magee
Journal:  Hypertension       Date:  2022-01-04       Impact factor: 9.897

8.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.

Authors:  Edgardo Abalos; Lelia Duley; D Wilhelm Steyn; Celina Gialdini
Journal:  Cochrane Database Syst Rev       Date:  2018-10-01

Review 9.  Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review.

Authors:  T Firoz; L A Magee; K MacDonell; B A Payne; R Gordon; M Vidler; P von Dadelszen
Journal:  BJOG       Date:  2014-05-16       Impact factor: 6.531

Review 10.  Impact of Antihypertensive Treatment on Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Louise M Webster; Frances Conti-Ramsden; Paul T Seed; Andrew J Webb; Catherine Nelson-Piercy; Lucy C Chappell
Journal:  J Am Heart Assoc       Date:  2017-05-17       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.